Ms. Joanne E. Kort, CNM, MPH Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 2937 Nw Highway 101, Unite A, Lincoln City, OR 97367 Phone: 541-614-0314 |
News Archive
Axiogenesis AG and iPS Academia Japan Inc. (Kyoto, Japan) announced that they have executed a non-exclusive agreement with iPS Academia (Kyoto, Japan) through which Axiogenesis obtains worldwide access to the extensive portfolio of induced pluripotent stem cell technology for iPSC-derived cardiomyocytes and other cell types, pioneered by Professor Shinya Yamanaka, Center for iPS Cell Research and Application at the University of Kyoto, Japan.
Parents' attitudes toward substance use may help to explain observed racial/ethnic variations in prescription drug misuse among teens, reports a study in the May Journal of Developmental & Behavioral Pediatrics, the official journal of the Society for Developmental and Behavioral Pediatrics.
For two years, a debate has raged over the study known as the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT), which sought to gauge the risks and benefits of different blood oxygen levels currently targeted in the care of premature infants.
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
› Verified 8 days ago